# Oxford BioTherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oxford-biotherapeutics

- Industry: Biotechnology
- Headquarters: Abingdon, UK
- Website: www.oxfordbiotherapeutics.com
- Total disclosed funding: $0.8M
- Latest round: Series B (Mar 30, 2005)
- Investors on record: 2

## About

Oxford BioTherapeutics Ltd specializes in developing innovative therapies for cancer treatment, leveraging proprietary technology to create targeted solutions for unmet medical needs in oncology.Founded in 2004 in Abingdon, UK, Oxford BioTherapeutics Ltd develops first-in-class cancer therapies. The company has completed 13 deals and recently raised GBP 4.2 mn in its latest funding round from Renaissance Capital Partners, bringing the total amount raised to GBP 4.2 mn. The current valuation of the company is GBP 69.022 mn. The company is led by Christian Rohlff, who also serves as the CEO.Oxford BioTherapeutics focuses on developing first-in-class cancer therapies through its innovative product offerings, which include Antibody-Drug Conjugates (ADCs), Immuno-oncology treatments, T-Cell Engagers (TCEs), and radiopharmaceuticals. The company leverages its proprietary OGAP®-Verify platform, a high-sensitivity proteomic technology that identifies novel cancer-specific targets. These therapies aim to improve patient outcomes by effectively targeting cancer cells while minimizing damage to healthy tissue, and are designed for pharmaceutical companies and research institutions primarily in North America and Europe.In 2022, Oxford BioTherapeutics reported revenue of GBP 17,409,630.30 and an EBITDA of GBP 994,941.20. The company generates revenue through strategic partnerships and collaborations, which typically involve licensing their proprietary technologies and co-developing therapeutic candidates, structured as B2B agreements.Oxford BioTherapeutics is focused on expanding its product line and growth into new markets. The company plans to launch new therapies developed through recent funding, specifically leveraging GBP 4.2 mn raised to enhance research and development capabilities. Additionally, Oxford BioTherapeutics is looking to increase its presence in North America and Europe, targeting partnerships that will facilitate access to broader markets.

## Funding rounds

- Series B, Mar 30, 2005, $0.8M — Oxford Capital Partners, Southeast Growth Fund

## Investors

- Oxford Capital Partners (https://capitalatlas.ai/funds/oxford-capital-partners) — Series B
- Southeast Growth Fund (https://capitalatlas.ai/funds/southeast-growth-fund) — Series B